Li Minxia, Sha Yabin, Zhang Xiuying
Clinical Laboratory, Danyang People's Hospital of Jiangsu Province Zhenjiang 212300, Jiangsu Province, China.
Blood Purification Center, First People's Hospital of Jinan Jinan 250011, Shandong Province, China.
Int J Clin Exp Pathol. 2017 Dec 1;10(12):11425-11437. eCollection 2017.
It is well known that microRNAs (miRNAs) are associated with tumor occurrence and development, and the functions of microRNA-22 (miR-22) have been investigated in numerous kinds of cancer. However, the significance of miR-22 in renal cell carcinoma (RCC) has not been fully explored. In this study, we found that miR-22 was down-regulated both in serum and tissues of RCC patients by using real time quantitative PCR (RT-qPCR) analyses. In addition, miR-22 was negatively associated with hepatic metastatic sites and lymphatic metastasis, as well as the clinical stages and prognosis. Moreover, the expression of miR-22 could be increased though surgical treatment in serum of RCC patients. Functional studies were performed to investigate the role of miR-22 in the progression of RCC. Data suggested that overexpression of miR-22 inhibited cell proliferation, migration and invasion in Caki-1 cells, whereas blockage of miR-22 could reverse these oncogenic effects. We also identified erb-b2 receptor tyrosine kinase (ERBB3) was a novel target of miR-22 in RCC cells. Consequently, our work provides evidence that the down-regulation of miR-22 expression contributed to RCC. And miR-22 may be a potential molecule biomarker for diagnose and therapy evaluation in RCC.
众所周知，微小RNA（miRNA）与肿瘤的发生和发展相关，并且已在多种癌症中研究了微小RNA-22（miR-22）的功能。然而，miR-22在肾细胞癌（RCC）中的意义尚未得到充分探索。在本研究中，我们通过实时定量PCR（RT-qPCR）分析发现，miR-22在RCC患者的血清和组织中均下调。此外，miR-22与肝转移部位、淋巴结转移以及临床分期和预后呈负相关。而且，通过手术治疗可使RCC患者血清中miR-22的表达增加。进行了功能研究以探讨miR-22在RCC进展中的作用。数据表明，miR-22的过表达抑制了Caki-1细胞的增殖、迁移和侵袭，而阻断miR-22可逆转这些致癌作用。我们还确定erb-b2受体酪氨酸激酶（ERBB3）是RCC细胞中miR-22的一个新靶点。因此，我们的工作提供了证据表明miR-22表达下调促成了RCC。并且miR-22可能是RCC诊断和治疗评估的潜在分子生物标志物。
